CRISPR/Cas9 en la diabetes: Ingeniería de células beta secretoras de insulina
CRISPR/Cas9 gene editing offers promising avenues for treating diabetes by restoring insulin production in beta cells. This article analyzes the current state of CRISPR/Cas9-based approaches, exploring their potential benefits, desafíos, and future directions in diabetes research and therapy.












